Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-ASIS PET Imaging of Tissue Factor in Cancer
NCT03790423Phase 1Completed
- Sponsor
- Rigshospitalet
- Start
- Jan 2019
- Primary completion
- Nov 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of 18F-ASIS in breast cancer, lung cancer, pancreatic cancer (PC) and 2 more, sponsored by Rigshospitalet. Primary endpoints: Biodistribution of 18F-ASIS at 4 hours and Dosimetry of 18F-ASIS at 4 hours. Started Jan 2019; status: completed.
02
Drugs
18F-ASIS
03
Conditions
breast cancerlung cancerpancreatic cancer (PC)ovarian cancerCervical Cancer (CC)
Beyond the preview
Go deeper on NCT03790423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790423.